Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

426 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of multivessel coronary disease with or without concurrent chronic total occlusion on one-year mortality in patients treated with primary percutaneous coronary intervention for cardiogenic shock.
van der Schaaf RJ, Claessen BE, Vis MM, Hoebers LP, Koch KT, Baan J Jr, Meuwissen M, Engstrom AE, Kikkert WJ, Tijssen JG, de Winter RJ, Piek JJ, Henriques JP. van der Schaaf RJ, et al. Among authors: henriques jp. Am J Cardiol. 2010 Apr 1;105(7):955-9. doi: 10.1016/j.amjcard.2009.11.014. Epub 2010 Feb 13. Am J Cardiol. 2010. PMID: 20346312
Impact of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump on prognostically important clinical outcomes in patients undergoing high-risk percutaneous coronary intervention (from the PROTECT II randomized trial).
Dangas GD, Kini AS, Sharma SK, Henriques JP, Claessen BE, Dixon SR, Massaro JM, Palacios I, Popma JJ, Ohman M, Stone GW, O'Neill WW. Dangas GD, et al. Among authors: henriques jp. Am J Cardiol. 2014 Jan 15;113(2):222-8. doi: 10.1016/j.amjcard.2013.09.008. Am J Cardiol. 2014. PMID: 24527505 Clinical Trial.
Evaluating the learning curve in the prospective Randomized Clinical Trial of hemodynamic support with Impella 2.5 versus Intra-Aortic Balloon Pump in patients undergoing high-risk percutaneous coronary intervention: a prespecified subanalysis of the PROTECT II study.
Henriques JP, Ouweneel DM, Naidu SS, Palacios IF, Popma J, Ohman EM, O'Neill WW. Henriques JP, et al. Am Heart J. 2014 Apr;167(4):472-479.e5. doi: 10.1016/j.ahj.2013.12.018. Epub 2014 Jan 3. Am Heart J. 2014. PMID: 24655695 Clinical Trial.
Prognostic value of access site and nonaccess site bleeding after percutaneous coronary intervention: a cohort study in ST-segment elevation myocardial infarction and comprehensive meta-analysis.
Kikkert WJ, Delewi R, Ouweneel DM, van Nes SH, Vis MM, Baan J Jr, Koch KT, Dangas GD, Mehran R, de Winter RJ, Peters RJ, Piek JJ, Tijssen JG, Henriques JP. Kikkert WJ, et al. Among authors: henriques jp. JACC Cardiovasc Interv. 2014 Jun;7(6):622-30. doi: 10.1016/j.jcin.2014.01.162. Epub 2014 May 14. JACC Cardiovasc Interv. 2014. PMID: 24835321 Free article. Review.
Experience from a randomized controlled trial with Impella 2.5 versus IABP in STEMI patients with cardiogenic pre-shock. Lessons learned from the IMPRESS in STEMI trial.
Ouweneel DM, Engstrom AE, Sjauw KD, Hirsch A, Hill JM, Gockel B, Tuseth V, van der Schaaf RJ, Henriques JP. Ouweneel DM, et al. Among authors: henriques jp. Int J Cardiol. 2016 Jan 1;202:894-6. doi: 10.1016/j.ijcard.2015.10.063. Epub 2015 Oct 9. Int J Cardiol. 2016. PMID: 26476989 Clinical Trial. No abstract available.
426 results